Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

199
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

190
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study

Pages

  41-46

Abstract

 Background: Treatment of Hepatitis C virus (HCV) infection with recently introduced Direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting. This study aimed to evaluate the efficacy and safety of generic Sofosbuvir/Ledipasvir (SOF/LDV) in a real-life clinical experience. Methods: In this prospective cohort study, patients with chronic HCV infection who referred to Middle East Liver Diseases (MELD) Center were included. Based on the patients’ condition, they were treated with SOF/LDV fixed-dose combination with or without ribavirin (RBV) for 12 or 24 weeks. Results: A total of 30 (M/F: 19/11) patients with chronic HCV genotype 1 infection with a mean age of 49. 8 years were treated with generic SOF/LDV with (9 patients) or without (11 patients) RBV for 12 (27 patients) or 24 (3 patients) weeks. Ten (33. 3%) had cirrhosis and 13 (43. 3%) with a previous history of Treatment with interferon (IFN)-based regimens. Among the 30 patients, 26 (86. 7%, 95% CI=70. 3%-94. 7%) achieved a rapid virologic response, 30 (100%, 95% CI=88. 7%-100%) achieved the end of Treatment response and 30 (100%, 95% CI=88. 7%-100%) achieved a sustained virologic response. No severe Treatment adverse event was observed however, 6 (20%) patients experienced mild to moderate adverse events. Conclusion: The Treatment of HCV genotype 1 infection with generic SOF/LDV found to be safe and effective even in patients with cirrhosis and previous history of Treatment with IFN-based Treatments.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    SHARAFI, HEIDAR, Alavian, Seyed Hoda, BEHNAVA, BITA, REZAEE ZAVAREH, MOHAMMAD SAEID, NIKBIN, MEHRI, & ALAVIAN, SEYED MOAYED. (2020). Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. CASPIAN JOURNAL OF INTERNAL MEDICINE, 11(1), 41-46. SID. https://sid.ir/paper/323588/en

    Vancouver: Copy

    SHARAFI HEIDAR, Alavian Seyed Hoda, BEHNAVA BITA, REZAEE ZAVAREH MOHAMMAD SAEID, NIKBIN MEHRI, ALAVIAN SEYED MOAYED. Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. CASPIAN JOURNAL OF INTERNAL MEDICINE[Internet]. 2020;11(1):41-46. Available from: https://sid.ir/paper/323588/en

    IEEE: Copy

    HEIDAR SHARAFI, Seyed Hoda Alavian, BITA BEHNAVA, MOHAMMAD SAEID REZAEE ZAVAREH, MEHRI NIKBIN, and SEYED MOAYED ALAVIAN, “Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study,” CASPIAN JOURNAL OF INTERNAL MEDICINE, vol. 11, no. 1, pp. 41–46, 2020, [Online]. Available: https://sid.ir/paper/323588/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top